Why Edwards Lifesciences (EW) Stock Is Down Today

Edwards Lifesciences (EW) is down 3.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely explanation is a muted or sell-the-news reaction to the latest Medicare coverage update for TAVR. The policy appears strategically positive for Edwards, but the company also said implementation will take time and did not lift its near-term outlook, which may have limited investor enthusiasm.

Details:

CMS posted its final national coverage determination for TAVR on September 10, updating Medicare policy for the procedure after a reconsideration process that Edwards had requested.

The updated framework supports broader flexibility in patient evaluation and treatment while preserving the multidisciplinary heart-team approach, which fits Edwards’ core valve franchise.

Edwards said the decision creates opportunity for patients and TAVR programs, but it also cautioned that implementation and adoption are expected to take time and kept its previously communicated 2026 guidance unchanged.

Edwards had already raised parts of its 2026 sales outlook in July, so some investors may be viewing the reimbursement update as largely anticipated rather than a fresh earnings catalyst. A recent SEC filing on an executive retirement also does not appear significant enough by itself to explain the full move.

Sources:

Edwards Lifesciences, CMS, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$EW Insider Trading Activity

$EW insiders have traded $EW stock on the open market 26 times in the past 6 months. Of those trades, 0 have been purchases and 26 have been sales.

Here’s a breakdown of recent trading of $EW stock by insiders over the last 6 months:

DONALD E JR BOBO (CVP,Strategy/Corp Development) has made 0 purchases and 5 sales selling 63,793 shares for an estimated $5,290,926.
DAVEEN CHOPRA (CVP, TMTT, Surgical & IHFM) has made 0 purchases and 3 sales selling 33,300 shares for an estimated $3,021,344.
SCOTT B. ULLEM (CVP, Chief Financial Officer) has made 0 purchases and 2 sales selling 13,000 shares for an estimated $1,040,544.
WAYNE MARKOWITZ (CVP, JAPAC) has made 0 purchases and 3 sales selling 11,014 shares for an estimated $944,962.
DANIEL J. LIPPIS (CVP, TAVR) has made 0 purchases and 8 sales selling 5,534 shares for an estimated $473,295.
BERNARD J ZOVIGHIAN (CEO) has made 0 purchases and 2 sales selling 3,443 shares for an estimated $291,116.
ANNETTE BRULS (CVP, EMEACLA) sold 2,644 shares for an estimated $237,907
ANDREW M. DAHL (SVP, Corporate Controller) has made 0 purchases and 2 sales selling 1,111 shares for an estimated $98,386.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive EW Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$EW Hedge Fund Activity

We have seen 615 institutional investors add shares of $EW stock to their portfolio, and 665 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JPMORGAN CHASE & CO added 22,783,175 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,060,966,010
JENNISON ASSOCIATES LLC removed 12,827,871 shares (-98.2%) from their portfolio in Q2 2026, for an estimated $1,160,409,210
ARISTOTLE CAPITAL MANAGEMENT, LLC added 8,665,712 shares (+inf%) to their portfolio in Q2 2026, for an estimated $783,900,307
BLACKROCK, INC. added 6,198,500 shares (+11.8%) to their portfolio in Q2 2026, for an estimated $560,716,310
FMR LLC removed 6,067,821 shares (-41.8%) from their portfolio in Q2 2026, for an estimated $548,895,087
ALLIANCEBERNSTEIN L.P. added 5,193,061 shares (+149.8%) to their portfolio in Q2 2026, for an estimated $469,764,298
WELLINGTON MANAGEMENT GROUP LLP removed 5,183,134 shares (-23.5%) from their portfolio in Q2 2026, for an estimated $468,866,301

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$EW Congressional Stock Trading

Members of Congress have traded $EW stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $EW stock by members of Congress over the last 6 months:

SENATOR ALAN ARMSTRONG purchased up to $15,000 on 03/27.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$EW Analyst Ratings

Wall Street analysts have issued reports on $EW in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 06/30/2026

To track analyst ratings and price targets for $EW, check out Quiver Quantitative's $EW forecast page.

$EW Price Targets

Multiple analysts have issued price targets for $EW recently. We have seen 10 analysts offer price targets for $EW in the last 6 months, with a median target of $100.0.

Here are some recent targets:

Joanne Wuensch from Citigroup set a target price of $110.0 on 07/08/2026
Vijay Kumar from Evercore ISI Group set a target price of $100.0 on 07/06/2026
Marie Thibault from BTIG set a target price of $110.0 on 06/30/2026
Shagun Singh from RBC Capital set a target price of $100.0 on 06/16/2026
Joshua Jennings from TD Cowen set a target price of $104.0 on 06/02/2026
Matt Miksic from Barclays set a target price of $110.0 on 04/27/2026
David Rescott from Baird set a target price of $87.0 on 04/24/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.